To evaluate the efficacy of zoledronate in reducing vertebral fracture incidence in postmenopausal women aged 50 to 60 without osteoporosis.
Key Findings:
6.6% of the zoledronate-placebo group experienced new morphometric vertebral fractures compared to 11.1% in the placebo-placebo group (RR = 0.59, 95% CI 0.36 to 0.97).
The number needed to treat to prevent one fracture was 22.
Zoledronate treatment groups showed higher bone density and lower bone turnover markers compared to placebo.
Interpretation:
Zoledronate administration significantly reduces the incidence of vertebral fractures in younger postmenopausal women without osteoporosis, suggesting its potential as a preventive treatment in this population.
Limitations:
Single-center study with low racial and ethnic diversity, limiting generalizability to broader populations.
Lack of insurance coverage for DEXA tests in women under 65 without certain risk factors may hinder implementation.
Conclusion:
Zoledronate is effective in lowering vertebral fracture risk in younger postmenopausal women lacking osteoporosis, warranting consideration for broader clinical application despite limitations.
